Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

NCT05707325 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor
Hematologic Malignancy

Interventions

DRUG: engineered red blood cell

Sponsor

Westlake Therapeutics